Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Protagonist Therapeutics reports initial phase II data on PTG-300 in polycythemia vera

May 8, 2020

Positive topline results from global phase III INNO2VATE program of vadadustat

May 6, 2020

Regenacy Pharmaceuticals discloses HDAC1 and/or HDAC2 inhibitors

April 21, 2020

Chinese regulatory approval granted to initiate phase II/III study of HBM-9161 in ITP

April 16, 2020

SP-8008 prevents thrombus formation without inducing bleeding by blocking vWF-GP Ib interaction

April 15, 2020

New t-PA, u-PA and plasmin inhibitors presented by Alxerion Biotech

April 9, 2020

Catalyst announces pivotal phase III design for MarzAA

April 8, 2020

FDA approves Reblozyl to treat anemia in MDS

April 6, 2020

FDA approves Sevenfact for hemophilia A and B

April 2, 2020

FORMA Therapeutics identifies new pyruvate kinase PKLR activators

April 2, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 7, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 7, 2024.
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...
Sanofi bets on Resalis’ oligonucleotide RES-010 for obesity
BioWorld
After missing out on the glucagon-like peptide 1 obesity market, Sanofi SA is prospecting for next-generation drugs and is making a strategic equity investment in...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.